Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes

View ORCID ProfileWinston A. Haynes, Kathy Kamath, Carolina Lucas, John Shon, Akiko Iwasaki
doi: https://doi.org/10.1101/2021.01.06.20248960
Winston A. Haynes
1Serimmune, Inc., Goleta, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Winston A. Haynes
Kathy Kamath
1Serimmune, Inc., Goleta, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Lucas
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Shon
1Serimmune, Inc., Goleta, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: john.shon@serimmune.com
Akiko Iwasaki
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
3Howard Hughes Medical Institute, Chevy Chase, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: john.shon@serimmune.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In 579 COVID patients’ samples collected between March and July of 2020, we examined the effects of non-synonymous mutations harbored by the circulating B.1.1.7 strain on linear antibody epitope signal for spike glycoprotein and nucleoprotein. At the antigen level, the mutations only substantially reduced signal in 0.5% of the population. Although some epitope mutations reduce measured signal in up to 6% of the population, these are not the dominant epitopes for their antigens. Given dominant epitope patterns observed, our data suggest that the mutations would not result in immune evasion of linear epitopes for a large majority of these COVID patients.

Competing Interest Statement

The authors declare the following competing interests: employment and personal financial interests including stock options at Serimmune, Inc: WAH, KK, JCS. Serimmune has submitted the following US Patent Application 63/114,939 SARS-CoV-2 Serum Antibody Profiling SUI-009PR4.

Funding Statement

No external funding was received. A.I. is an investigator of the Howard Hughes Medical Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yale Cohort: Yale University IRB, Approved SBCH Cohort: Santa Barbara Cottage Health IRB (SBCH IRB), Waived (Human Subjects Exemption, de-identified remnant samples) BCA Cohort: New York Blood Center (NYBC) IRB, Waived (de-identified remnant samples) LabCorp Cohort: LabCorp clinical network IRB, Waived (de-identified remnant samples) BioIVT Cohort: BioIVT clinical network IRB, Waived (de-identified remnant samples)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes
Winston A. Haynes, Kathy Kamath, Carolina Lucas, John Shon, Akiko Iwasaki
medRxiv 2021.01.06.20248960; doi: https://doi.org/10.1101/2021.01.06.20248960
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes
Winston A. Haynes, Kathy Kamath, Carolina Lucas, John Shon, Akiko Iwasaki
medRxiv 2021.01.06.20248960; doi: https://doi.org/10.1101/2021.01.06.20248960

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1262)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10055)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)